713predictive markers , 221
VeraTag™ assay system , 223
brain tumors ( see Brain cancer
management)
breast cancer ( see Breast cancer
management)
cancer cells, selective destruction of
epigenetics role , 258–259
hyperbaric oxygen , 260
PLK4 , 261
sphingolipids , 260
transformation-induced oxidative
stress , 260–261
cell surface glycoproteins , 235–236
challenges , 365
chemotherapy
PET imaging , 230–231
pharmacogenetics , 266–269
pharmacogenomics , 264–265
proteomic analysis , 228
real-time apoptosis monitoring , 228–229
serum nucleosomes , 229–230
targeted microbubbles , 230
tissue systems biology approach , 231
tumor biopsy, sensitivity , 224–225
classifi cation , 199, 200
COLTHERES consortium , 366
computational models
cancer signaling bridges , 270–271
kinetically tailored treatment , 269
mathematical model , 270
computer and imaging technologies , 366–367
developmental factors , 200
drug resistance , 271
anaplastic lymphoma kinase , 273
cancer recurrence, surgery , 276–277
chemogenomic approach , 274–275
in leukemia , 275–276
MDR, overexpression , 272–273
metabolic profi ling , 273–274
P-glycoprotein , 272
P53 mutations , 273
splice variants, role of , 272
systems biology approach , 277
topoisomerase levels , 275
ERCC1-XPF , 223–224
gastrointestinal cancer ( see Gastrointestinal
cancer)
genomic approaches
gene expression pattern , 225
genetic variations , 227
molecular level, mutation detection ,
226–227
PI3K and MAPK signaling pathways , 226RDAT , 227
tumor biopsies , 225–226
head and neck cancer , 325–326
hematological cancer risk, blood DNA
sequence , 219
hematological malignancies ( see
Hematological malignancies
management)
ICGC , 368–369
immunotherapy
cancer dormancy , 239
functional antibody-based therapies ,
237–239
integrated genome-wide analysis , 367–368
liver cancer ( see Liver cancer
management)
lung cancer ( see Lung cancer management)
lymphomas ( see Lymphomas)
malignant melanoma ( see Malignant
melanoma)
metastasis , 277–278
molecular diagnostics , 202
aptamers , 232–233
BEAMing technology , 206–207
cancer genes, catalog of , 205
chromosomal alterations , 203–204
CTCs ( see Circulating tumor cells
(CTCs))
CUP , 207
CYP450 activity modulation , 211
DNA methylation, QD-based test for , 213
DNA repair biomarkers , 208
fl uorescence in situ hybridization , 208
gene expression profi ling , 208–210
gene-level information, pathway-level
information , 212
genetic code , 217
LOH detection of , 206
metastatic cancer , 233–234
microarrays, classifi cation , 204–205
molecular imaging technologies ,
214–217
monoclonal antibodies , 234–235
MRD detection , 207–208
NGS-based oncology test system , 203
oncogenic pathways signatures ,
212–213
RNA splicing event analysis , 203
molecular profi ling , 235
nanobiotechnology , 256–257
non-genetic factors , 227–228
oncoproteomics , 261–262
ovarian cancer ( see Ovarian cancer
management)Index